Group 1 - The core point of the article is that Zhonghui Biotech-B (02627) has seen a significant stock price increase following the approval of its quadrivalent influenza virus subunit vaccine by the National Medical Products Administration of China, marking it as the first and only vaccine of its kind approved for the entire population in China [1][2] - The stock price rose over 8%, with a current increase of 7.49%, reaching HKD 51.25, and a trading volume of HKD 18.463 million [1] - The quadrivalent influenza virus subunit vaccine is a major upgrade from traditional virus split vaccines, offering comprehensive protection, high purity of antigen components, and lower risk of adverse reactions [1] Group 2 - The vaccine developed by Zhonghui Biotech-B utilizes a third-generation technology route, optimizing production processes to extract only effective antigen components—hemagglutinin (HA) and neuraminidase (NA)—which significantly enhances antigen purity and reduces impurity content [2] - This new vaccine is expected to fill a market gap as it is the only vaccine product included in the preliminary review list for innovative drugs under commercial insurance in China [1][2]

Core Viewpoint - Zhonghui Biotech-B (02627) has received approval from the National Medical Products Administration of China for its quadrivalent influenza virus subunit vaccine, making it the first and only approved vaccine for all age groups in China [1][2]. Group 1: Company Developments - Zhonghui Biotech-B's stock rose over 8%, currently trading at 51.25 HKD with a transaction volume of 18.463 million HKD [1]. - The quadrivalent influenza virus subunit vaccine is a significant upgrade from traditional split virus vaccines, offering comprehensive protection, high purity of antigen components, and lower risk of adverse reactions [1][2]. Group 2: Market Position - The newly approved vaccine is the only vaccine product included in the preliminary review list for innovative drugs under commercial insurance, highlighting its rarity and potential to fill a market gap [1]. - The vaccine utilizes a third-generation technology route, optimizing production processes to extract effective antigen components, which enhances safety, immune response, and overall quality compared to second-generation split vaccines [2].

今日上午港股 1. 优必选（09880）涨近2% ，获某国内知名企业2.5亿元人形机器人订单，将在年内启动该合同交 付。 2. 金风科技（02208）涨近2% ，可再生能源加速发放，公司风机业务毛利率如期明显改善。 3.苹果概念股走强， 高伟电子（01415）涨近1% ， 蓝思科技（06613）涨近1% 。 4. 中创新航（03931）涨超14% ，今日拿下印度大型电池项目合作，公司正加强全球化产能布局。 5. 瑞浦兰钧（00666）涨超9.5% ，近期头部储能电池企业已接近满产，部分开始提价。 点击蓝字，关注我们 1. 谷歌C(GOOG.US)涨9.01% ，垄断案获重大胜利，无需剥离Chrome和安卓系统。 2. 极氪(ZK.US)涨1.12% ，集团销量连续六个月超4万台大关。 6. 佑驾创新（02431）跌近0.1% ，公司与深圳邮政，东部公交达成战略合作，推进无人物流场景落 地。 7. 狮腾控股（02562）涨近5.7% ，突出多模型大型语言模型平台Geene M2。 8. 中慧生物-B(02627 ) 涨超3% ，四价流感病毒亚单位 疫苗 上市申请获国家药监局批准。 9. 佳鑫国际资源(03858 ...

Core Viewpoint - Zhonghui Biotech-B (02627) has seen a stock price increase of over 3%, currently trading at 50.4 HKD with a transaction volume of 5.0766 million HKD, following the approval of its quadrivalent influenza virus subunit vaccine by the National Medical Products Administration of China [1][1][1] Group 1 - The company announced that its quadrivalent influenza virus subunit vaccine has received approval for the 6-35 month age group, making it the first and only vaccine of its kind approved for the entire population in China [1][1] - The new vaccine represents a significant upgrade over traditional virus split vaccines, offering comprehensive protection, high purity of antigen components, and lower risk of adverse reactions [1][1][1]

北京商报讯（记者 王寅浩 实习记者 宋雨盈）9月3日，中慧生物发布公告称，国家药品监督管理局已批 准公司针对6—35月龄人群的四价流感病毒亚单位疫苗的新药申请。公告显示，该款疫苗成为中国首款 且唯一一款获批上市的全人群全剂量四价流感病毒亚单位疫苗。 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration of China for its quadrivalent influenza virus subunit vaccine, making it the first and only approved vaccine of its kind for the entire population in China [1] Company Overview - The company is a vaccine manufacturer based in China, focusing on the research, development, manufacturing, and commercialization of innovative vaccines and traditional vaccines using new technologies [1] - The company aims to replace traditional and imported vaccines in China with high-quality vaccines and expand its competitive advantages to international markets [1] Product Details - The newly approved quadrivalent influenza virus subunit vaccine is designed for individuals aged 6 to 35 months and offers comprehensive protection, high purity of antigen components, and a low risk of adverse reactions [1] - The product represents a significant upgrade over traditional virus-inactivated vaccines [1] - The company's product pipeline includes the quadrivalent influenza virus subunit vaccine, a lyophilized human rabies vaccine under development, and other vaccines in the research phase [1]

Core Viewpoint - Zhonghui Biotech-B (02627) has received approval from the National Medical Products Administration of China for its quadrivalent influenza virus subunit vaccine aimed at the 6-35 month age group, marking it as the first and only approved vaccine of its kind in China for the entire population and all dosage levels [1] Company Overview - The company is headquartered in China and focuses on the research, development, manufacturing, and commercialization of innovative vaccines and traditional vaccines using new technological methods [1] - The company tracks global infectious disease incidence and vaccine development trends to determine its product pipeline, emphasizing high-quality vaccines to replace traditional and imported vaccines in China while expanding its competitive advantage to international markets [1] Product Details - The newly approved quadrivalent influenza virus subunit vaccine is a significant upgrade over traditional virus split vaccines, offering comprehensive protection, high purity of antigen components, and lower risk of adverse reactions [1] - The company's product line includes the quadrivalent influenza virus subunit vaccine, a lyophilized human rabies vaccine under development, and other vaccines in the pipeline [1]

Core Viewpoint - Zhonghui Biotech-B (02627.HK) has received approval from the National Medical Products Administration of China for its quadrivalent influenza virus subunit vaccine aimed at the population aged 6 to 35 months, marking it as the first and only approved vaccine of its kind in China for the entire population and all dosage levels [1] Group 1 - The vaccine represents a significant upgrade over traditional virus split vaccines, offering comprehensive protection, high purity of antigen components, and a lower risk of adverse reactions [1]

Core Viewpoint - Zhonghui Biotech-B (02627) experienced a significant stock price increase of 1.35%, closing at 52.5 HKD, following the release of its interim results for the six months ending June 30, 2025, which showed a remarkable revenue growth of 919.25% year-on-year [1] Financial Performance - The company's revenue for the reporting period reached 71.123 million RMB, marking a substantial increase compared to the same period last year [1] - Gross profit amounted to 60.781 million RMB, indicating strong profitability [1] - Research and development expenditures were significantly increased, totaling 98.848 million RMB [1] Company Overview - Zhonghui Biotech is a China-based vaccine company focused on the research, development, manufacturing, and commercialization of innovative vaccines and traditional vaccines using new technologies [1] - The company's product pipeline includes two core products: a quadrivalent influenza virus subunit vaccine and an investigational freeze-dried human rabies vaccine, along with 11 other vaccines in development [1] - All vaccine products and those under development are classified as Category II vaccines in China [1] Development Platforms - The company has established three comprehensive vaccine development support platforms: a gene engineering and protein expression and purification platform, an mRNA vaccine research platform, and an adjuvant development and production platform [1] - As of June 30, 2025, Zhonghui Biotech successfully obtained IND approvals for nine investigational vaccines from the National Medical Products Administration [1]

Core Viewpoint - Zhonghui Biotech-B (02627) reported a significant increase in revenue for the six months ending June 30, 2025, with total revenue reaching RMB 71.123 million, representing a year-on-year growth of 919.25% [1] Financial Performance - The company's gross profit for the same period was RMB 60.781 million [1] - Research and development expenses amounted to RMB 98.848 million [1] Company Overview - Established in 2015, the company is a vaccine manufacturer based in China, focusing on innovative vaccines and traditional vaccines using new technological methods [1] - The vaccine pipeline includes products that meet domestic needs and comply with global standards, featuring two core products: a quadrivalent influenza virus subunit vaccine and an investigational freeze-dried human rabies vaccine [1] - The company has an additional 11 investigational vaccines targeting various diseases with high vaccination demand [1] Research and Development Capabilities - The company has established three comprehensive vaccine development support platforms: a gene engineering and protein expression and purification platform, an mRNA vaccine research platform, and an adjuvant development and production platform [1] - Unique proprietary technology platforms, including large-scale amplification, polysaccharide conjugation, and microbiology and immunology research platforms, enhance the company's R&D capabilities [1] - As of June 30, 2025, the company successfully obtained IND approvals for nine investigational vaccines from the National Medical Products Administration [1]